Clinical value of plasma p-tau217 in identifying mild cognitive impairment due to Alzheimer's disease: A comparative multimarker analysis
Journal of Alzheimer’s Disease · 20.11.2026
DOI: 10.1177/13872877261507291 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 20.11.2026. Verfasst von Xiaocong Guo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Zigong First People's Hospital, Zigong, China. Die Arbeit nennt 44 Literaturangaben. Gefördert von: ZiGong Science and Technology Bureau, Medical Research Project of Sichuan Medical Association.
Themen: Demenz
Abstract (Originalsprache)
Background
Alzheimer's disease (AD) causes progressive neurodegeneration, and mild cognitive impairment due to AD (AD-MCI) represents a critical window for intervention. Invasive or costly diagnostic tools hinder early detection. The 2024 NIA-AA criteria recognize plasma p-tau217 as a core blood-based biomarker for prodromal AD, supporting the clinical translation of peripheral pathological markers.
Objective
To compare plasma biomarker profiles between AD-MCI and cognitively unimpaired (CU) participants, evaluate the diagnostic performance of p-tau217, p-tau181, and Aβ 42 /Aβ 40 ratio for detecting this AD-MCI group, and assess correlations between these plasma biomarkers and cognitive function in the cohort.
Methods
Fifty-one participants were enrolled from a single center in China. Plasma p-tau217, p-tau181, and the Aβ 42 /Aβ 40 ratio were measured using a domestically developed fluorescent magnetic-particle immunoassay (FMIA). ROC curve analysis was used to assess diagnostic performance, and Spearman correlation analysis was used to test biomarker-cognition associations.
Results
Plasma p-tau217 yielded the highest AUC = 0.923 (cut-off: 4.35 pg/mL; sensitivity 80.9%; specificity 96.6%), outperforming p-tau181 (AUC = 0.902) and the Aβ 42 /Aβ 40 ratio (AUC = 0.714). Only weak, non-significant correlations were observed between biomarkers and cognitive scores in the AD-MCI group (r ranged from −0.22 to 0.05).
Conclusions
Plasma p-tau217 measured using this FMIA showed excellent diagnostic performance for AD-MCI in a cohort from southwestern China. The population- and platform-specific cut-offs differed from those reported in Western cohorts using Simoa-based assays. Weak cognitive correlations suggest that plasma p-tau217 primarily reflects brain amyloid and tau pathology rather than cognitive severity, supporting its use for community-based triage screening for early AD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Zigong First People's Hospital, Zigong, China.
- Department of Neurology, Zigong First People's Hospital, Zigong, China.
ORCID-Profile: Xiaocong Guo
Förderung
- ZiGong Science and Technology Bureau
- Medical Research Project of Sichuan Medical Association
Zitieren
APA
Guo, X., Liu, Y., Wang, Z., & Xu, X. (2026). Clinical value of plasma p-tau217 in identifying mild cognitive impairment due to Alzheimer's disease: A comparative multimarker analysis. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877261507291
Vancouver
Guo X, Liu Y, Wang Z, Xu X. Clinical value of plasma p-tau217 in identifying mild cognitive impairment due to Alzheimer's disease: A comparative multimarker analysis. Journal of Alzheimer’s Disease. 2026. doi:10.1177/13872877261507291
BibTeX
@article{Guo2026,
author = {Guo, Xiaocong and Liu, Yue and Wang, Zilin and Xu, Xiaoya},
title = {Clinical value of plasma p-tau217 in identifying mild cognitive impairment due to Alzheimer's disease: A comparative multimarker analysis},
journal = {Journal of Alzheimer’s Disease},
year = {2026},
doi = {10.1177/13872877261507291}
}
EUVIMED